CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 12 enrolled
Drug / intervention
Enalaprilatdrug
Likely dose
Enalaprilat 0.01 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00741156
NCT00741156Phase 3Completed
CompareCT.gov

The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution After the Bidirectional Cavopulmonary Connection

The Hospital for Sick Children·interventional·Posted Aug 26, 2008·Updated Dec 18, 2015

In Brief

A Phase 3 clinical trial evaluating Enalaprilat for Hypertension and Congestive Cardiomyopathy. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The primary objective of this study is to study the acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, Congestive Cardiomyopathy
CountriesCanada
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 26, 2008
Enrollment StartJul 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.8 years ago

Interventions

Enalaprilatdrug

Enalaprilat will be administered intravenously i.v. 0.005 - 0.01 mg/kg i.v. over 1 minute